Focused On-demand Library for Platelet factor 4 variant

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P10720

UPID:

PF4V_HUMAN

Alternative names:

C-X-C motif chemokine 4 variant; CXCL4L1; PF4alt; PF4var1

Alternative UPACC:

P10720; A1L4S0

Background:

Platelet factor 4 variant, also known by its alternative names such as C-X-C motif chemokine 4 variant, CXCL4L1, PF4alt, and PF4var1, plays a crucial role as an inhibitor of angiogenesis and endothelial cell chemotaxis in vitro. This protein's unique functions position it as a key player in the regulation of blood vessel formation and cellular movement.

Therapeutic significance:

Understanding the role of Platelet factor 4 variant could open doors to potential therapeutic strategies. Its ability to inhibit angiogenesis and endothelial cell chemotaxis highlights its potential as a target for developing treatments aimed at controlling abnormal blood vessel growth and migration, which are critical processes in various diseases.